Evidence map›Paper›PMID 35742992›Full record

ArticleInternational journal of molecular sciences2022

Synthesis and Anti-Cancer Activity of New Pyrazolinyl-Indole Derivatives: Pharmacophoric Interactions and Docking Studies for Identifying New EGFR Inhibitors.

Habibullah Khalilullah, Deepak K Agarwal, Mohamed J Ahsan, Surender S Jadav, Hamdoon A Mohammed, Masood Alam Khan, Salman A A Mohammed, Riaz Khan

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Habibullah KhalilullahDepartment of Pharmaceutical Chemistry and Pharmacognosy, Unaizah College of Pharmacy, Qassim University, Unaizah 51911, Saudi Arabia.ORCID 0000-0002-7401-6254
Deepak K AgarwalDepartment of Pharmaceutical Chemistry, Alwar College of Pharmacy, Alwar 302 023, Rajasthan, India.
Mohamed J AhsanDepartment of Pharmaceutical Chemistry, Maharishi Arvind College of Pharmacy, Jaipur 302 023, Rajasthan, India.ORCID 0000-0002-6919-5489
Surender S JadavCentre for Molecular Cancer Research (CMCR), Vishnu Institute of Pharmaceutical Education and Research (VIPER), Narsapur 502 313, Telangana, India.
Hamdoon A MohammedDepartment of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Qassim 51452, Saudi Arabia.ORCID 0000-0003-2896-6790
Masood Alam KhanCollege of Applied Sciences, Qassim University, Qassim 51452, Saudi Arabia.
Salman A A MohammedDepartment of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Qassim 51452, Saudi Arabia.ORCID 0000-0002-9250-100X
Riaz KhanDepartment of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Qassim 51452, Saudi Arabia.
Qassim University · SAAlwar Pharmacy College · INNational Institute of Pharmaceutical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Newly designed series of indole-containing pyrazole analogs, pyrazolinylindoles, were synthesized, and their structures were confirmed based on the spectral data of the

Indexed as

Antineoplastic AgentsLeukemiaCell Line, TumorCell ProliferationErbB ReceptorsHumansImatinib MesylateIndolesMolecular Docking SimulationMolecular StructureProtein Kinase InhibitorsStructure-Activity RelationshipAntineoplastic AgentsEGFR protein, humanErbB ReceptorsImatinib MesylateIndolesProtein Kinase Inhibitorsanti-cancercell linesEGFRindoleligand dockingmolecular modelingpyrazolepyrazolinyl-indoletyrosine kinase

Identifiers

PMID35742992
PMCPMC9223872
OpenAlexW4282579867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.